Cutaneous immune-related adverse events in patients with metastatic melanoma on antiprogrammed cell death protein 1 and anticytotoxic T-lymphocyte–associated protein 4 therapy: A retrospective cohort study

• Sheida Naderi-Azad, BSc,
• Faisal Sickandar, MD,
• Rossanna C. Pezo, MD, PhD, FRCP

Affiliations

Sheida Naderi-Azad, BSc

University of Toronto Faculty of Medicine, Toronto, Ontario, Canada

Faisal Sickandar, MD

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada

Rossanna C. Pezo, MD, PhD, FRCP

Sunnybrook Research Institute, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Division of Medical Oncology and Hematology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Correspondence to: Rossanna C. Pezo, MD, PhD, FRCP, Sunnybrook Odette Cancer Centre, Division of Medical Oncology and Hematology, 2075 Bayview Avenue, Toronto, ON, Canada M4N 3N5